Back to Search
Start Over
Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis
- Source :
- Urologic oncology. 36(6)
- Publication Year :
- 2017
-
Abstract
- Background Prognostic biomarkers for patients with clear cell renal cell carcinoma (ccRCC), particularly those receiving therapy targeting angiogenesis, are not well established. In this study, we examined the correlations of monocarboxylate transporter 1 (MCT1) and MCT4, 2 critical transporters for glycolytic metabolism, with various clinicopathological parameters as well as survival of patients with ccRCC and those treated with vascular endothelial growth factor receptor (VEGFR) inhibitors. Methods A cohort of 150 ccRCC patients were recruited into this study. All patients underwent radical or partial nephrectomy as the first-line treatment, and 38 received targeted therapy (sorafenib or sunitinib) after the surgery. Expression levels of MCT1, MCT4, and CD34 were examined by immunohistochemistry. Correlations between MCT1 or MCT4 expression and different clinicopathological parameters or patient survival were analyzed among all as well as patients receiving targeted therapy. Results MCT1 or MCT4 expression did not significantly correlate with sex, age, tumor diameter, microvascular density, tumor staging, pathological Furmann grade, or MSKCC (P>0.05). High expression of either MCT1 or MCT4 significantly correlated with reduced overall survival (OS) and progression-free survival (PFS) among the total cohort of ccRCC patients. For patients receiving targeted therapy, high expression of either MCT1 or MCT4 significantly correlated with reduced PFS, but not OS. Both conditions were independent prognostic biomarkers for reduced PFS among all patients or those receiving targeted therapy. Conclusion MCT1 and MCT4 are prognostic biomarkers for patients with ccRCC or those receiving targeted therapy. High expression of these 2 proteins predicts reduced PFS in these patients.
- Subjects :
- 0301 basic medicine
Oncology
Male
Vascular Endothelial Growth Factor A
Indoles
Angiogenesis
medicine.medical_treatment
Muscle Proteins
Targeted therapy
Cohort Studies
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
Sunitinib
Medicine
biology
Neovascularization, Pathologic
Symporters
Middle Aged
Sorafenib
Prognosis
Nephrectomy
Kidney Neoplasms
Survival Rate
Monocarboxylate transporter 1
030220 oncology & carcinogenesis
Lymphatic Metastasis
Female
medicine.drug
Monocarboxylic Acid Transporters
Niacinamide
medicine.medical_specialty
Urology
03 medical and health sciences
Internal medicine
Biomarkers, Tumor
Humans
Pyrroles
Progression-free survival
Carcinoma, Renal Cell
business.industry
Phenylurea Compounds
medicine.disease
Clear cell renal cell carcinoma
030104 developmental biology
biology.protein
business
Follow-Up Studies
Subjects
Details
- ISSN :
- 18732496
- Volume :
- 36
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Urologic oncology
- Accession number :
- edsair.doi.dedup.....d291c3fd3a64679ba762aebd9f6f8e10